Table 2 Outcomes of PET-2-negative and PET-2-positive patients assigned to receive combined-modality treatment.
From: Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma
PET-2-negative | PET-2-positive | |||||
|---|---|---|---|---|---|---|
DS 1–2 (N = 353) | DS 3 (N = 218) | DS ≥ 4 (N = 122) | ||||
Follow-up (months) | ||||||
For disease status | 65 (63–67) | 63 (62–66) | 64 (60–68) | |||
For survival status | 67 (65–72) | 65 (63–71) | 65 (62–70) | |||
Tumor events | ||||||
Progression | 0 | 0 | 6 | (5%) | ||
Early relapse (within one year after end of treatment) | 3 | (1%) | 4 | (2%) | 2 | (2%) |
Late relapse | 15 | (4%) | 12 | (6%) | 12 | (10%) |
Any tumor event | 18 | (5%) | 16 | (7%) | 20 | (16%) |
Causes of death | ||||||
Hodgkin lymphoma | 1 | (<1%) | 1 | (1%) | ||
Toxicity of second-line therapy | 0 | 1 | (<1%) | 0 | ||
Second primary malignancy | 4 | (1%) | 2 | (1%) | 1 | (1%) |
Cardiovascular disease | 1 | (<1%) | 1 | (<1%) | ||
Unclear | 3 | (1%) | 1 | (<1%) | 1 | (1%) |
Any event | 9 | (3%) | 5 | (2%) | 3 | (2%) |
